Synopsis
Synopsis
0
USDMF
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Emcyt
2. Estracyt
3. Estramustin Phosphate
4. Estramustine Phosphate Sodium
5. Estramustinphosphate
6. Leo 275
7. Leo-275
8. Leo275
9. Nsc 89199
10. Nsc-89199
11. Nsc89199
12. Phosphate Sodium, Estramustine
13. Phosphate, Estramustin
1. 2998-57-4
2. Estramustinum
3. Estramustina
4. Estramustinum [inn-latin]
5. Estramustina [inn-spanish]
6. Estradiol 3-(n,n-bis(2-chloroethyl)carbamate)
7. Nsc-89201
8. 17beta-estradiol 3-(bis(2-chloroethyl)carbamate)
9. Chembl1575
10. Estradiol 3-(bis(2-chloroethyl)carbamate)
11. Estradiol 3-[bis(2-chloroethyl)carbamate]
12. Chebi:4868
13. [(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,n-bis(2-chloroethyl)carbamate
14. Ro 22-2296/000
15. 35lt29625a
16. Leo 275
17. Ncgc00164581-01
18. Ro-222296000
19. Estradiol, 3-[bis(2-chloroethyl)carbamate]
20. Ro-22-2296000
21. Dsstox_cid_26458
22. Dsstox_rid_81632
23. Dsstox_gsid_46458
24. (8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl Bis(2-chloroethyl)carbamate
25. Ro 21-8837
26. Nsc 89201
27. Estra-1,3,5(10)-triene-3,17beta-diol, 3-[bis(2-chloroethyl)carbamate]
28. Disodium (1s,10r,11s,14s,15s)-5-{[bis(2-chloroethyl)carbamoyl]oxy}-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-yl Phosphate
29. Cas-2998-57-4
30. Estradiol, 3-(bis(2-chloroethyl)carbamate)
31. Estradiol 3-[n,n-bis(2-chloroethyl)carbamate]
32. Mls002701936
33. 17.beta.-estradiol 3-[bis(2-chloroethyl)carbamate]
34. Estramustine (usan/inn)
35. Estramustin
36. Nsc89201
37. Estramustine [usan:inn:ban]
38. Unii-35lt29625a
39. Einecs 221-076-3
40. Estramustine [mi]
41. Estramustine [inn]
42. Ro-22-2296/000
43. Estramustine [usan]
44. Schembl4252
45. Estramustin Sodium Phosphate
46. Estramustine [vandf]
47. Bidd:gt0482
48. Estramustine [who-dd]
49. Gtpl9076
50. Dtxsid8046458
51. Hms3715d22
52. Zinc4099032
53. Tox21_112207
54. Bdbm50333646
55. Lmst02010038
56. (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl Bis(2-chloroethyl)carbamate
57. Akos025402444
58. Tox21_112207_1
59. Ac-9163
60. Ccg-221220
61. Db01196
62. Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-(bis(2-chloroethyl)carbamate)
63. Ncgc00164581-02
64. As-12259
65. Nci60_041982
66. Hy-103711
67. Cs-0035073
68. Ro-22-2296-000
69. D04066
70. 998e574
71. A876334
72. Q412939
73. W-106963
74. Carbamic Acid, Bis(2-chloroethyl)-, 17beta-hydroxyestra-1,3,5(10)-trien-3-yl Ester
75. Estra-1,3,5(10)-triene-3,17-diol, 3-(bis(2-chloroethyl)carbamate), (17b)-
76. Estra-1,3,5(10)-triene-3,17-diol, 3-(bis(2-chloroethyl)carbamate), (17beta)-
77. Estra-1,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]
78. Estra-1,5(10)-triene-3,17-diol, 3-[bis(2-chloroethyl)carbamate], (17.beta.)-
79. Bis-(2-chloro-ethyl)-carbamic Acid 17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl Ester
| Molecular Weight | 440.4 g/mol |
|---|---|
| Molecular Formula | C23H31Cl2NO3 |
| XLogP3 | 4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 439.1680992 g/mol |
| Monoisotopic Mass | 439.1680992 g/mol |
| Topological Polar Surface Area | 49.8 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 585 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard moiety becomes active and participates in alkylation of DNA or other cellular components.. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage.
Antineoplastic Agents, Alkylating
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026) (See all compounds classified as Antineoplastic Agents, Alkylating.)
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
L01XX11
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01X - Other antineoplastic agents
L01XX - Other antineoplastic agents
L01XX11 - Estramustine
Route of Elimination
The metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate.
20 hours
Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors.
Global Sales Information
ABOUT THIS PAGE
A Estramustine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Estramustine, including repackagers and relabelers. The FDA regulates Estramustine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Estramustine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Estramustine supplier is an individual or a company that provides Estramustine active pharmaceutical ingredient (API) or Estramustine finished formulations upon request. The Estramustine suppliers may include Estramustine API manufacturers, exporters, distributors and traders.
click here to find a list of Estramustine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Estramustine CEP of the European Pharmacopoeia monograph is often referred to as a Estramustine Certificate of Suitability (COS). The purpose of a Estramustine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Estramustine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Estramustine to their clients by showing that a Estramustine CEP has been issued for it. The manufacturer submits a Estramustine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Estramustine CEP holder for the record. Additionally, the data presented in the Estramustine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Estramustine DMF.
A Estramustine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Estramustine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Estramustine suppliers with CEP (COS) on PharmaCompass.
Estramustine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Estramustine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Estramustine GMP manufacturer or Estramustine GMP API supplier for your needs.
A Estramustine CoA (Certificate of Analysis) is a formal document that attests to Estramustine's compliance with Estramustine specifications and serves as a tool for batch-level quality control.
Estramustine CoA mostly includes findings from lab analyses of a specific batch. For each Estramustine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Estramustine may be tested according to a variety of international standards, such as European Pharmacopoeia (Estramustine EP), Estramustine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Estramustine USP).
LOOKING FOR A SUPPLIER?
